tradingkey.logo

Bioxcel Therapeutics Announces 33% Enrollment In Serenity At-Home Pivotal Phase 3 Safety Trial

ReutersMar 7, 2025 12:01 PM

- BioXcel Therapeutics Inc BTAI.O:

  • BIOXCEL THERAPEUTICS ANNOUNCES 33% ENROLLMENT IN SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA

  • BIOXCEL THERAPEUTICS INC: TOPLINE DATA EXPECTED IN SECOND HALF OF 2025

  • BIOXCEL THERAPEUTICS: SERENITY PHASE 3 SAFETY TRIAL TOPLINE DATA EXPECTED IN H2 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI